EcoDrugPlus

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSGACG00000001062
Gene Symbol: PIK3R1
1 Cross references
197 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSGACG00000015520
Gene Symbol: PIK3R2
1 Cross references
190 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSGACG00000014045
Gene Symbol: PLA2G10
1 Cross references
233 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSGACG00000004825
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSGACG00000014485
Gene Symbol: GART
2 Cross references
213 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSGACG00000014244
Gene Symbol: GART
1 Cross references
213 Possible Orthologues:

Plasminogen

Ensembl ID : ENSGACG00000005858
Gene Symbol: PLG
1 Cross references
255 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSGACG00000004146
Gene Symbol: PLAT
1 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSGACG00000009674
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSGACG00000018005
Gene Symbol: PDGFRB
1 Cross references
199 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSGACG00000016526
Gene Symbol: PLK1
2 Cross references
187 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSGACG00000017794
Gene Symbol: PARP2
1 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).